cbdMD (YCBD)
Develops cannabinoid wellness, pet CBD, mushroom supplements, and THC beverages.
Something off on this page? Send us feedback.
Produces hemp-derived cannabinoid wellness products, pet CBD, functional-mushroom supplements, and THC beverages under several brands. Revenue comes from direct e-commerce and wholesale distribution, using a hybrid production model with in-house activity and contract manufacturers.
Builds a consumer-wellness portfolio around hemp-derived cannabinoids, serving human and pet customers through the cbdMD, Bluebird Botanicals, and Paw CBD brands. Products include CBD oils, gummies, capsules, soft gels, topicals, and veterinarian-formulated pet tinctures and chews, alongside ATRx functional-mushroom supplements and Oasis hemp-derived THC social beverages.
Sells primarily through its websites, third-party marketplaces, wholesale team, retailers, specialty health and pet channels, and beverage distributors. The United States is its core market, with Oasis distribution focused in the Southeast and Texas; the company also pursues international distributors. It sets specifications and quality oversight while combining selected internal work with contract manufacturing and independent laboratory testing.
Operates in a fragmented cannabinoid category shaped by federal and state product rules, FDA policy, digital advertising and payment access, distributor acceptance, hemp suppliers, manufacturing partners, and laboratory testing.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $2.1M · Total debt $2.2M · Total assets $13.1M · Shareholders' equity $8.2M
- Revenue
- $5.6M
- Operating income
- −$1.1M
- Net income
- −$1.1M
No dividends on record.
| Institutions | 8.19% | 917.7K shares | |
|---|---|---|---|
| 27 holders · as of Jun 30, 2026 | |||
| Insiders | 5.12% | 573.5K shares | |
| 1 holder · as of May 8, 2025 | |||
| Strategic holders | 7.35% | 823.1K shares | |
| 1 holder · as of May 12, 2025 | |||
| Other | 79.34% | 8.89M shares | |
| remainder | |||
11.21M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
CRC Investment Fund LP ("CRC LP")Strategic | 7.35% | 823,125 | filed May 12, 2025 |
Porter Jeffrey HInsider | 5.12% | 573,530 | filed May 8, 2025 |
Worth Venture Partners, LLCInstitution | 1.65% | 184,796 | as of Jun 30, 2026 |
CSS LLC/ILInstitution | 1.23% | 137,621 | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 1.07% | 119,645 | as of Jun 30, 2026 |
Insider tradesForm 4
Nothing filed in the last 12 months.
- Direxion Daily CSI China Internet Index Bull 2X ETF
Broad CBD, pet, functional-mushroom, and hemp-THC wellness overlap.
- Laird Superfood
Functional-mushroom supplements and wellness-beverage overlap.
CompareAfter hours
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| cbdMD | $0.4943 | −0.76% | $4.6M | — | — | 0.2 | +20.6% |
| Direxion Daily CSI China Internet Index Bull 2X ETF | $19.60 | −0.38% | $146.9M | — | — | — | — |
| Laird Superfood | $3.57 | −1.65% | $39.9M | — | 13.6 | 0.6 | +244.4% |
| Median | — | 13.6 | 0.6 | +244.4% |